The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2025 | Novel developments in treating IO-induced toxicities in lung cancer
Michel Obeid, MD, PhD, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, discusses the value of deep immune profiling in identifying biomarkers for major immunotherapy (IO)-induced toxicities such as myocarditis, cytokine release syndrome, and arthritis. Anti-IL-6 therapy can reduce mortality related to these life-threatening conditions, where IL-6 is a common biomarker across these conditions, and targeting it with therapy has shown promising results in reducing mortality and severity. This interview took place at the European Lung Cancer Congress (ELCC) 2025 in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
